Hennion & Walsh Asset Management, Inc. C4 Therapeutics, Inc. Transaction History
Hennion & Walsh Asset Management, Inc.
- $1.89 Billion
- Q2 2024
A detailed history of Hennion & Walsh Asset Management, Inc. transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Hennion & Walsh Asset Management, Inc. holds 142,832 shares of CCCC stock, worth $918,409. This represents 0.03% of its overall portfolio holdings.
Number of Shares
142,832Holding current value
$918,409% of portfolio
0.03%Shares
1 transactions
Others Institutions Holding CCCC
# of Institutions
119Shares Held
53.8MCall Options Held
331KPut Options Held
145K-
Ra Capital Management, L.P. Boston, MA4.88MShares$31.4 Million0.34% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT4.85MShares$31.2 Million0.12% of portfolio
-
Black Rock Inc. New York, NY4.55MShares$29.3 Million0.0% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT4.05MShares$26.1 Million1.9% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.56MShares$22.9 Million0.0% of portfolio
About C4 Therapeutics, Inc.
- Ticker CCCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,913,800
- Market Cap $315M
- Description
- C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...